InvestorsHub Logo

ddls

03/13/24 8:17 PM

#327566 RE: JustGoDeep #327564

You're living in a dream world. BIEL is finished.😭
Bearish
Bearish

GetSeriousOK

03/14/24 9:41 AM

#327573 RE: JustGoDeep #327564

"Proper Marketing-Partner And Sales For Biel?" This is a repeat of your hype from ten years ago. Tsunamis and trips to the moon. When will you face reality?

"There Are Hundreds Of Millions In Potential Sales To Be Made Here." You said that ten years ago. It was bullshit then and it's bullshit now.

"IE: Just 10 Million Units A Year At $35 Each Is $350 Million In Gross Sales." that would be e.g not i.e. but no matter because it's bullshit. This little company has trouble achieving $350 thousand gross revenues annually, but you think there's even the slightest chance they can increase gross sales to $350 MILLION? And you must know that the distributors don't pay them $35 per unit. t's more like $10-$12 per unit. Even a direct sale from the shelf in CVS or the cyber shelf on Amazon wouldn't gross $35 for BIEL.

"Now Imagine 100 or 200 or 300 Or More Million Unit Sales A Year." Why stop there. Imagine 100 or 200 or 300 BILLION unit sales per year. If you're going to spew nonsense, go big.

One GREAT Or 2-3 Really Good Patners And The Potential Here Is Realized. This is just tragic. This is your hype from 10 years ago and it's never going to stop, is it.

Nopainact Could Do This By Itself. well that is the one and only concrete thing you said, and it's nonsense. The NOPAIN Act is Medicare reimbursement for hospital or outpatient surgery only. That alone scales the potential client base down to far less than your ridiculous 100-200-300 million units per year. And let's not forget that at this time, the ActiPatch/RecoveryRx doesn't meet the criteria for reimbursement because they don't have the necessary clinical proof that the device reduces opioid use.

And this is where you claim that BIEL's old survey will satisfy the CMS. It absolutely will NOT. It was just a survey and it didn't prove ANYTHING about opioid use. Their follow-up questions didn't ask about opioid use -- they asked a broad question about use of pain meds in general.